XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -0.83%1.93B | -2.34%553.04M | -2.20%458.89M | 0.51%471.31M | 1.13%450.06M | -3.35%1.95B | 0.33%566.3M | 4.98%469.19M | -5.28%468.93M | -12.84%445.02M |
Operating revenue | -0.83%1.93B | -2.34%553.04M | -2.20%458.89M | 0.51%471.31M | 1.13%450.06M | -3.35%1.95B | 0.33%566.3M | 4.98%469.19M | -5.28%468.93M | -12.84%445.02M |
Cost of revenue | -12.53%950.32M | -12.98%252.06M | -14.05%226.96M | -11.40%238.46M | -11.64%232.83M | -11.08%1.09B | -8.86%289.68M | -1.22%264.07M | -13.21%269.15M | -19.30%263.51M |
Gross profit | 13.90%982.97M | 8.80%300.97M | 13.07%231.93M | 16.55%232.85M | 19.68%217.22M | 8.53%863.04M | 12.18%276.63M | 14.21%205.13M | 8.00%199.78M | -1.37%181.51M |
Operating expense | 5.82%831.57M | 9.64%206.46M | 14.78%222.33M | -1.47%195.91M | 0.91%206.87M | 1.93%785.83M | -4.87%188.31M | 10.60%193.69M | -17.67%198.82M | 31.11%205M |
Selling and administrative expenses | 1.60%552.23M | -0.72%138.9M | 4.48%137.05M | 3.98%136.27M | -0.99%140.01M | -6.82%543.54M | 8.79%139.91M | -0.93%131.17M | -34.47%131.05M | 15.59%141.41M |
-Selling and marketing expense | -7.37%376.09M | -0.34%97.36M | -3.96%90.82M | -15.50%95.07M | -8.30%92.84M | 7.41%406.01M | -1.95%97.69M | 5.02%94.57M | 13.29%112.51M | 13.76%101.24M |
-General and administrative expense | 28.08%176.14M | -1.59%41.55M | 26.29%46.22M | 122.25%41.2M | 17.42%47.17M | -33.02%137.53M | 45.74%42.22M | -13.59%36.6M | -81.59%18.54M | 20.50%40.17M |
Research and development costs | 15.29%279.34M | 39.58%67.56M | 36.41%85.29M | -12.00%59.64M | 5.14%66.86M | 29.15%242.29M | -30.20%48.4M | 46.34%62.52M | 63.33%67.78M | 86.88%63.59M |
Operating profit | 96.07%151.4M | 7.01%94.51M | -16.02%9.6M | 3,751.72%36.94M | 144.07%10.35M | 218.06%77.22M | 81.56%88.32M | 155.34%11.43M | 101.70%959K | -184.93%-23.49M |
Net non-operating interest income expense | -38.87%3.1M | 235.50%2.21M | 172.25%893K | 235.81%1.15M | -96.56%302K | 369.88%5.06M | -14.73%-1.63M | -298.71%-1.24M | -396.85%-849K | 2,126.79%8.78M |
Non-operating interest income | ---- | ---- | 35.73%1.43M | 54.10%1.65M | 105.93%2.19M | 142.13%4.68M | 7.13%1.49M | 520.59%1.06M | 346.67%1.07M | 699.25%1.06M |
Non-operating interest expense | ---- | ---- | -74.73%513K | -79.51%409K | 88.77%2.2M | 12.01%7.53M | -56.11%2.34M | 381.04%2.03M | 372.99%2M | 113.16%1.17M |
Total other finance cost | 60.91%-3.1M | -384.65%-2.21M | -90.04%26K | 220.00%90K | 96.46%-314K | -171.44%-7.92M | 130.68%775K | 350.00%261K | 83.97%-75K | -46,831.58%-8.88M |
Other net income (expense) | 47.95%-901K | -43.27%-1.44M | 145.10%879K | -138.42%-7.55M | 39.26%-2.87M | -145.61%-1.73M | -106.22%-1M | -143.67%-1.95M | ||
Gain on sale of security | ---- | ---- | 47.95%-901K | -43.27%-1.44M | 145.10%879K | -138.42%-7.55M | 39.26%-2.87M | -145.61%-1.73M | -106.22%-1M | -143.67%-1.95M |
Income before tax | 106.75%154.5M | 15.38%96.71M | 13.31%9.59M | 4,204.59%36.65M | 169.21%11.54M | 77.67%74.73M | 97.22%83.82M | 6.33%8.47M | 97.77%-893K | -152.59%-16.67M |
Income tax | 98.09%39.78M | 13.79%24.77M | 88.32%3.45M | 697.31%8.6M | 164.61%2.97M | -35.60%20.08M | -17.70%21.77M | 27.05%1.83M | 115.14%1.08M | -144.12%-4.6M |
Net income | 109.93%114.71M | 15.94%71.94M | -7.40%6.14M | 1,523.59%28.06M | 170.96%8.57M | 402.47%54.64M | 286.63%62.05M | 1.75%6.64M | 94.02%-1.97M | -156.73%-12.07M |
Net income continuous Operations | 109.93%114.71M | 15.94%71.94M | -7.40%6.14M | 1,523.59%28.06M | 170.96%8.57M | 402.47%54.64M | 286.63%62.05M | 1.75%6.64M | 94.02%-1.97M | -156.73%-12.07M |
Minority interest income | 126.86%3.14M | -17.89%849K | 65.41%-101K | 18.45%1.07M | 604.58%1.32M | -27.98%1.39M | 59.32%1.03M | -403.45%-292K | 41.19%905K | -137.92%-262K |
Net income attributable to the parent company | 109.49%111.57M | 16.52%71.1M | -9.85%6.25M | 1,038.35%26.99M | 161.34%7.24M | 494.94%53.26M | 296.21%61.02M | 5.29%6.93M | 91.44%-2.88M | -157.36%-11.81M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 109.49%111.57M | 16.52%71.1M | -9.85%6.25M | 1,038.35%26.99M | 161.34%7.24M | 494.94%53.26M | 296.21%61.02M | 5.29%6.93M | 91.44%-2.88M | -157.36%-11.81M |
Basic earnings per share | 114.74%2.04 | 19.27%1.3 | -8.33%0.11 | 1,080.00%0.49 | 161.90%0.13 | 533.33%0.95 | 319.23%1.09 | 9.09%0.12 | 91.07%-0.05 | -161.76%-0.21 |
Diluted earnings per share | 115.91%1.9 | 20.59%1.23 | -8.33%0.11 | 1,020.00%0.46 | 157.14%0.12 | 528.57%0.88 | 308.00%1.02 | 20.00%0.12 | 91.07%-0.05 | -165.63%-0.21 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |